Active substanceInosineInosine
Similar drugsTo uncover
  • Inosie-F®
    solution in / in 
    Europharm (UK) Co., Ltd.     United Kingdom
  • Inosine
    solution in / in 
    Ama Pharm, OOO     China
  • Inozin-Eskom
    solution in / in 
    ESKOM NPK, OAO     Russia
  • Riboxin
    solution in / in 
    ATOLL, LLC     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    VALENTA PHARM, PAO     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    IRBITSK HFZ, OJSC     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    solution in / in 
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    MAKSFARM, OJSC     Russia
  • Riboxin
    solution in / in 
  • Riboxin
    pills inwards 
    BINNOFARM, CJSC     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    OZONE, LLC     Russia
  • Riboxin
    pills inwards 
    BIOSINTEZ, PAO     Russia
  • Riboxin
    pills inwards 
  • Riboxin
    pills inwards 
    DALHIMFARM, OJSC     Russia
  • Riboxin
    solution in / in 
    BIOSINTEZ, PAO     Russia
  • Riboxin
    pills inwards 
    NORTH STAR, CJSC     Russia
  • Riboxin
    capsules inwards 
    MINSKINTERKAPS, UP     Republic of Belarus
  • Riboxin
    solution in / in 
    VEROPHARM SA     Russia
  • Riboxin
    pills inwards 
    Mapichem AG     Switzerland
  • Riboxin
    solution in / in 
    Mapichem AG     Switzerland
  • Riboxin
    solution in / in 
    DALHIMFARM, OJSC     Russia
  • Riboxin
    solution in / in 
    ELLARA, LTD.     Russia
  • Riboxin
    solution in / in 
    GROTEKS, LLC     Russia
  • Riboxin
    solution in / in 
    VELFARM, LLC     Republic of San Marino
  • Riboxin of Avexime
    pills inwards 
  • Riboxin Beefus
    solution in / in 
    UPDATE OF PFC, CJSC     Russia
  • Riboxin-Vial
    solution in / in 
    VIAL, LLC     Russia
  • Riboxin-LexT
    pills inwards 
  • Riboxin-Ferein
    pills inwards 
    BRYNTSALOV-A, CJSC     Russia
  • ASFARMA, LLC     Russia
  • Dosage form: & nbspsolution for intravenous administration
    Composition:

    Inosine (Riboxin) 20 mg.

    Excipients: hexamethylenetetramine (methenamine) 2 mg; solution of sodium hydroxide (sodium hydroxide) 1 M to pH 7.8-8.6; water for injection up to 1 ml.

    Description:

    Transparent colorless or slightly colored liquid.

    Pharmacotherapeutic group:metabolic
    ATX: & nbsp

    C.01.E.B   Other drugs for the treatment of heart disease

    Pharmacodynamics:

    Riboxin is a derivative (nucleoside) of purine, a precursor of adenosine triphosphate (ATP). Refers to a group of drugs that stimulate metabolic processes. Has antihypoxic and antiarrhythmic effect. Increases the energy balance of the myocardium, improves coronary circulation, prevents the consequences of intraoperative kidney ischemia. It takes a direct part in the exchange of glucose and promotes the activation of metabolism under conditions of hypoxia and in the absence of ATP.

    Activates the metabolism of pyruvic acid necessary to ensure the normal process of tissue respiration, and also promotes the activation of xanthine dehydrogenase. Stimulates the synthesis of nucleotides, enhances the activity of certain enzymes of the Krebs cycle. Penetrating into cells, it has a positive effect on metabolic processes in the myocardium - it increases the strength of the heart contractions and promotes more complete relaxation of the myocardium in diastole, as a result of which the stroke volume increases.The mechanism of antiarrhythmic action is not fully understood.

    Reduces platelet aggregation, activates the regeneration of tissues (especially the myocardium and the mucous membrane of the gastrointestinal tract).

    Pharmacokinetics:

    Metabolized in the liver with the formation of glucuronic acid and subsequent its oxidation. In an insignificant amount excreted in the urine.

    Indications:Complex treatment of myocardial infarction, coronary heart disease, cardiac arrhythmias caused by the use of cardiac glycosides, against myocardial dystrophy after the infectious diseases.
    Diseases of the liver (hepatitis, cirrhosis, fatty degeneration), urocoppororphyria.
    Operations on an isolated kidney (as a means of pharmacological protection when the circulation is turned off).
    Contraindications:

    Hypersensitivity to the drug, gout, hyperuricemia, pregnancy, lactation, age under 18 years (efficacy and safety not established).

    Carefully:With renal failure.
    Dosing and Administration:

    The drug is administered intravenously slowly or dripwise (40-60 drops per minute). Treatment begins with the introduction of 200 mg (10 mL of 2% solution) once a day, then, with good tolerability, the dose is increased to 400 mg (20 ml of 2% solution) 1 to 2 times a day. Duration of treatment is 10-15 days.

    Jet injection of the drug is possible for acute heart rhythm disorders in a single dose of 200-400 mg (10-20 ml 2% solution).

    For pharmacological protection of the kidneys subjected to ischemia, riboxin is injected intravenously in a single dose of 1.2 g (60 ml of a 2% solution) 5 to 15 minutes before clotting the renal artery, and then another 0.8 g (40 ml of a 2% solution) immediately after the restoration of blood circulation. With a drip in the vein 2% the drug solution is diluted in a 5% solution of dextrose (glucose) or isotonic sodium chloride solution (up to 250 ml).

    Side effects:

    Allergic reactions: skin itchy skin hyperemia (drug should be discarded).

    Rarely: increased concentration of uric acid in the blood, exacerbation of gout (with prolonged use).

    Form release / dosage:

    Solution for intravenous administration, 20 mg / ml.

    Packaging:

    10 ml into neutral glass ampoules.

    For 10 ampoules, together with the instructions for use and the ampoule scarifier, are placed in a cardboard box.

    10 ampoules are placed in a contour mesh package made of a polyvinyl chloride film.1 circuit cell pack together with the instructions for use and the ampoule scarifier are put in a pack of cardboard

    When using ampoules with a notch, dot or ring fracture, the ampoule scaper is not inserted.

    Storage conditions:

    In a dry, the dark place at a temperature of 15 to 25 °FROM.

    Keep out of the reach of children.

    Shelf life:

    3 years.

    Do not use after the time specified on the packaging.

    Terms of leave from pharmacies:On prescription
    Registration number:LSR-009348/09
    Date of registration:19.11.2009
    The owner of the registration certificate:MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC Russia
    Manufacturer: & nbsp
    Representation: & nbspMOSHIMFARM PREPARATES them. NA Semashko OJSC MOSHIMFARM PREPARATES them. NA Semashko OJSC Russia
    Information update date: & nbsp22.10.2015
    Illustrated instructions
      Instructions
      Up